基于影像的卒中后癫痫风险评分IsCHEMiA的开发与国际验证
本研究利用美国麻省总医院1436例首发急性缺血性卒中患者的数据,开发了一个包含梗死大小、皮层受累、出血转化、早期癫痫发作、大脑中动脉受累及年龄小于65岁六项变量的IsCHEMiA评分,用于预测卒中后癫痫(PSE)。该模型在国际多队列(共2534例)中验证,c统计量为0.826至0.870,校准良好,且优于SeLECT评分。
要点
- IsCHEMiA评分包含6项变量:梗死大小、皮层受累、出血转化、早期癫痫发作、大脑中动脉受累、年龄小于65岁。
- 模型在多个国际队列中区分度良好,c统计量为0.826至0.870,1年和3年校准良好。
- IsCHEMiA评分在全部队列中预测PSE的能力优于SeLECT评分(c统计量0.848 vs 0.782,p<0.0001)。
核心结论
- IsCHEMiA评分是一个改进且易于应用的预测模型,可用于预测首发缺血性卒中后的卒中后癫痫。
研究设计与样本
- 研究分析了美国麻省总医院连续入组的首发急性缺血性卒中患者的临床和神经影像特征,最终衍生队列包含1436例患者,平均年龄67.4岁,男性占54.7%。
- 采用竞争风险回归(全因死亡为竞争事件),通过基于Akaike信息准则的后向逐步消除法建立最终多变量模型。
- 模型在香港(玛丽医院和律敦治医院)和日本(国立循环器病研究中心)的3个国际队列中共2534例患者中进行外部验证。
主要发现
- 卒中后癫痫(定义为卒中后7天以上出现或复发非诱发性癫痫发作)在整体研究人群中发生率为5.5%。
- 最终模型包含六个独立预测因子:梗死大小、皮层受累、出血转化、早期癫痫发作、大脑中动脉受累和年龄小于65岁,构成IsCHEMiA评分。
- 模型区分度在各队列中一致,c统计量分别为美国0.870、香港玛丽医院0.852、香港律敦治医院0.857、日本0.826。
- 模型在整体验证队列中卒中后1年和3年校准良好。
- IsCHEMiA评分在所有队列和整体研究人群中预测PSE均优于SeLECT评分(c统计量0.848 vs 0.782,z=5.170,p<0.0001)。
关键数值与推荐
- IsCHEMiA评分包含6项变量:梗死大小、皮层受累、出血转化、早期癫痫发作、大脑中动脉受累、年龄小于65岁。
- IsCHEMiA评分3分对应1年PSE风险2%、5年风险6%;评分≥8分对应1年风险67%、5年风险78%。
临床怎么用
- IsCHEMiA评分可用于首发缺血性卒中后PSE的风险分层,帮助识别高风险患者进行个体化管理。
- 该评分可能为未来抗癫痫发生治疗的临床试验提供指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Stroke is one of the most common causes of adult-onset epilepsy. We aimed to develop a model to predict poststroke epilepsy (PSE) after a first-ever ischemic stroke, incorporating neuroimaging features of incident stroke. METHODS: We analyzed clinical and neuroimaging features of patients with first-ever acute ischemic stroke consecutively admitted to Massachusetts General Hospital, United States. We performed competing risk regression with all-cause mortality as a competing event and derived the final multivariable model using backward stepwise elimination by the Akaike Information Criterion. We externally validated the model in 3 international cohorts in Hong Kong (Queen Mary Hospital [HK-QMH], Ruttonjee Hospital [HK-RH]) and Japan (National Cerebral and Cardiovascular Center) by discrimination and calibration and compared its performance with the SeLECT and SeLECT2.0 scores. RESULTS: We included a final derivative cohort of 1,436 patients with a mean age of 67.4 years and a slight male predominance (54.7%), along with a total of 2,534 patients in the validation cohorts. PSE, defined as the occurrence or recurrence of unprovoked seizure >7 days after stroke, occurred in 5.5% of the overall study population. Six variables (infarct size [Is], cortical involvement [C], hemorrhagic transformation [H], early seizures [E], MCA involvement [Mi], and age younger than 65 [A]) were independent predictors included in the final model and formed the IsCHEMiA score. Model discrimination was consistent across all cohorts, with c-statistics of 0.870 (United States), 0.852 (HK-QMH), 0.857 (HK-RH), and 0.826 (Japan). The model was well calibrated at 1 and 3 years after stroke in the overall validation cohort. The IsCHEMiA score improved the prediction of PSE compared with SeLECT in all cohorts and the overall study population (c-statistic 0.848 vs 0.782, z = 5.170, p < 0.0001). For example, an IsCHEMiA score of 3 predicts a low risk of PSE at 1 year (2%) and 5 years (6%) while an IsCHEMiA score ≥8 predicts a high risk at 1 year (67%) and 5 years (78%). DISCUSSION: The IsCHEMiA score is an improved and readily applicable predictive model developed and validated using international stroke cohorts in the modern era of reperfusion therapies. It serves as a foundation for personalized management and may guide future clinical trials on antiepileptogenic therapies in acute ischemic stroke.
引用
- Leung WCY, Tanaka T, Donahue RA, et al. Development and International Validation of a Novel Imaging-Based Risk Score (IsCHEMiA) for the Prediction of Poststroke Epilepsy. Neurology. 2026. PMID: 41490217. doi:10.1212/WNL.0000000000214486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。